Regeneron Officer Files Form 144 to Sell $175K in Common Stock
REGENERON PHARMACEUTICALS, INC.
Subscribe to track REGN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 144 Proposed Sale Notice: Regeneron Pharmaceuticals, Inc. (REGN) ā¢ Insider: Jason Pitofsky (Officer) ā¢ Shares Proposed to Sell: 180 Common Stock ā¢ Estimated Total Value: $175,204.80 (~$973.36/share) ā¢ Broker: J.P. Morgan Securities LLC ā¢ Approximate Date of Sale: 11/04/2026 ā¢ Significance: Low
Comprehensive Analysis
Executive Summary
On November 4, 2026, Jason Pitofsky, an Officer of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), submitted a Form 144 filing signaling an intention to sell up to 180 shares of common stock through broker J.P. Morgan Securities LLC, representing an aggregate market value of approximately $175,204.80.
Transaction Details
- Security: Common Stock
- Shares Proposed for Sale: 180
- Estimated Aggregate Market Value: $175,204.80 (implied price of ~$973.36 per share)
- Shares Outstanding: 101,630,713
- Approximate Sale Date: November 4, 2026
- Acquisition Origin: The shares were inherited on August 13, 2024, from Freddy Runne.
- Remarks: The filing notes that the shares are to be sold by Stephanie Pitofsky.
Market and Insider Context
- Trading Significance: Low. The disposition represents an extremely fractional percentage (<0.001%) of Regeneron's 101.6M common shares outstanding.
- Context: The transaction originates from inherited securities and is modest in size relative to typical insider liquidity events at large-cap biopharmaceutical companies.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.